An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Period Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions
Latest Information Update: 10 Mar 2026
At a glance
- Drugs AD 116 (Primary)
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors Addpharma
Most Recent Events
- 10 Mar 2026 New trial record